ASLAN Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
ASLAN Pharmaceuticals to present at H.C. Wainwright conference
09/07/2023 - 07:00 AM
SAN MATEO, Calif. and SINGAPORE, Sept. 07, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will give an in-person company presentation at the H.C. Wainwright 25th Annual Global Investment Conference, to be held both virtually and in-person at the Lotte New York Palace Hotel in New York City, from September 11 to 13, 2023.
ASLAN management will also be available for one-on-one meetings with investors throughout the conference. Please contact your representative at H.C. Wainright to schedule a meeting.
Company Presentation Information
Format: Live presentation with webcast link
Presenter: Carl Firth, CEO
Date: Monday, September 11, 2023
Time: 10:30 am ET
A replay of the presentation can be accessed directly at this link and will be posted to the Investor Relations section of ASLAN’s website and available for 90 days.
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is developing eblasakimab , a potential first-in-class antibody targeting the IL-13 receptor in moderate-to-severe atopic dermatitis (AD) with the potential to improve upon current biologics used to treat allergic disease, and has recently reported positive topline data from a Phase 2b dose ranging study in moderate-to-severe AD. ASLAN is also developing farudodstat , a potent oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) as a potential first-in-class treatment for alopecia areata (AA) in a Phase 2a proof-of-concept trial with an interim readout expected in 1Q 2024. ASLAN has teams in San Mateo, California, and in Singapore. For additional information please visit the website or follow ASLAN on LinkedIn .
Media and IR contacts
ASLAN Pharmaceuticals Ltd
ASLN Rankings
#4588 Ranked by Stock Gains
ASLN Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
Cayman Islands
City
190 Elgin Avenue
About ASLN
aslan pharmaceuticals (aslan, 6497.tt) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. aslan targets diseases that are both highly prevalent in asia and orphan indications in the united states and europe. led by a senior management team with extensive experience in global and regional development and commercialization, aslan is headquartered in singapore and has offices in taiwan and china. aslan’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. aslan’s partners include array biopharma, bristol-myers squibb, almirall and csl.
